Cascades posts transcript of Q2 2026 results conference call
Reuters2026/08/11 14:07- Cascades held its Q2 2026 results call on Aug. 6 with CEO Hugues Simon and CFO Allan Hogg.
- Packaging sales rose to $772 million; adjusted EBITDA increased to $120 million; margin improved to 15.5% on higher volumes and pricing.
- Tissue sales climbed to $409 million; adjusted EBITDA rose to $35 million; margin held at 8.6% despite raw material and transportation inflation.
- Q3 outlook calls for sequential improvement; annual run-rate adjusted EBITDA expected to exceed $600 million in H2 2026.
- New U.S. tariffs could hit certain exports at 50%; management estimates net impact at under 5% of adjusted EBITDA run rate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
